Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor
Kurt Schönfeld, Christiane Sahm, Congcong Zhang, et al.
Molecular Therapy (2014) Vol. 23, Iss. 2, pp. 330-338
Open Access | Times Cited: 311

Showing 1-25 of 311 citing articles:

NK cells and cancer: you can teach innate cells new tricks
Maelig Morvan, Lewis L. Lanier
Nature reviews. Cancer (2015) Vol. 16, Iss. 1, pp. 7-19
Closed Access | Times Cited: 1009
Targeting natural killer cells in cancer immunotherapy
Camille Guillerey, Nicholas D. Huntington, Mark J. Smyth
Nature Immunology (2016) Vol. 17, Iss. 9, pp. 1025-1036
Closed Access | Times Cited: 977
CAR-NK cells: A promising cellular immunotherapy for cancer
Guozhu Xie, Han Dong, Yong Liang, et al.
EBioMedicine (2020) Vol. 59, pp. 102975-102975
Open Access | Times Cited: 603
NK cell-based cancer immunotherapy: from basic biology to clinical development
Sizhe Liu, Vasiliy Galat, Yekaterina Galat, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 488
Engineering Natural Killer Cells for Cancer Immunotherapy
Katayoun Rezvani, Rayne H. Rouce, Enli Liu, et al.
Molecular Therapy (2017) Vol. 25, Iss. 8, pp. 1769-1781
Open Access | Times Cited: 390
Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells
Hans Klingemann, Laurent Boissel, Frances Toneguzzo
Frontiers in Immunology (2016) Vol. 7
Open Access | Times Cited: 377
First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia.
Xiaowen Tang, Lin Yang, Zheng Li, et al.
PubMed (2018) Vol. 8, Iss. 6, pp. 1083-1089
Closed Access | Times Cited: 369
ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
Congcong Zhang, Michael C. Burger, Lukas Jennewein, et al.
JNCI Journal of the National Cancer Institute (2015) Vol. 108, Iss. 5
Open Access | Times Cited: 346
Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors
Ombretta Melaiu, Valeria Lucarini, Loredana Cifaldi, et al.
Frontiers in Immunology (2020) Vol. 10
Open Access | Times Cited: 333
CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells
Jianfeng Han, Jianhong Chu, Wing Keung Chan, et al.
Scientific Reports (2015) Vol. 5, Iss. 1
Open Access | Times Cited: 306
NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy
Garnet Suck, Marcus Odendahl, Paulina Nowakowska, et al.
Cancer Immunology Immunotherapy (2015) Vol. 65, Iss. 4, pp. 485-492
Open Access | Times Cited: 284
NK cell-based immunotherapy for cancer
Fang Fang, Weihua Xiao, Zhigang Tian
Seminars in Immunology (2017) Vol. 31, pp. 37-54
Closed Access | Times Cited: 277
CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances
Karama Makni‐Maalej, Maysaloun Merhi, Varghese Inchakalody, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 277
Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity
Congcong Zhang, Pranav Oberoi, Sarah Oelsner, et al.
Frontiers in Immunology (2017) Vol. 8
Open Access | Times Cited: 275
3D model for CAR ‐mediated cytotoxicity using patient‐derived colorectal cancer organoids
Theresa Schnalzger, Marnix HP de Groot, Congcong Zhang, et al.
The EMBO Journal (2019) Vol. 38, Iss. 12
Open Access | Times Cited: 264
Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy
Carla Riera‐Domingo, Annette Audigé, Sara Granja, et al.
Physiological Reviews (2019) Vol. 100, Iss. 1, pp. 1-102
Open Access | Times Cited: 250
Advantages and applications of CAR-expressing natural killer cells
Wolfgang Glienke, Ruth Esser, Christoph Priesner, et al.
Frontiers in Pharmacology (2015) Vol. 6
Open Access | Times Cited: 232
Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer
Rohtesh S. Mehta, Katayoun Rezvani
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 232
Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma
Nadja Müller, Susanne Michen, Stefanie Tietze, et al.
Journal of Immunotherapy (2015) Vol. 38, Iss. 5, pp. 197-210
Open Access | Times Cited: 218
DAP12-Based Activating Chimeric Antigen Receptor for NK Cell Tumor Immunotherapy
Katrin Töpfer, Marc Cartellieri, Susanne Michen, et al.
The Journal of Immunology (2015) Vol. 194, Iss. 7, pp. 3201-3212
Open Access | Times Cited: 216
A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases
Xilin Chen, Jianfeng Han, Jianhong Chu, et al.
Oncotarget (2016) Vol. 7, Iss. 19, pp. 27764-27777
Open Access | Times Cited: 214
CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies
A Romański, Christoph Uherek, Gesine Bug, et al.
Journal of Cellular and Molecular Medicine (2016) Vol. 20, Iss. 7, pp. 1287-1294
Open Access | Times Cited: 207
CAR-NK for tumor immunotherapy: Clinical transformation and future prospects
Wenxiu Wang, Jingting Jiang, Changping Wu
Cancer Letters (2019) Vol. 472, pp. 175-180
Open Access | Times Cited: 190
Strategies to Address Chimeric Antigen Receptor Tonic Signaling
Adam Ajina, John Maher
Molecular Cancer Therapeutics (2018) Vol. 17, Iss. 9, pp. 1795-1815
Open Access | Times Cited: 188
Tricking the balance: NK cells in anti-cancer immunity
Jens Pahl, Adelheid Cerwenka
Immunobiology (2015) Vol. 222, Iss. 1, pp. 11-20
Closed Access | Times Cited: 184
Page 1 - Next Page

Scroll to top